EW Quote, Financials, Valuation and Earnings

Artivion, Inc. has a net margin of 18.82% compared to Edwards Lifesciences Corp.'s net margin of 5.73%. Edwards Lifesciences Corp.'s return on equity of 13.19% beat Artivion, Inc.'s return on equity of -2.63%.

Edwards Lifesciences Corp. has a consensus price target of $96.44, signalling upside risk potential of 13.29%. On the other hand Artivion, Inc. has an analysts' consensus of $51.71 which suggests that it could grow by 16.61%. Given that Artivion, Inc. has higher upside potential than Edwards Lifesciences Corp., analysts believe Artivion, Inc. is more attractive than Edwards Lifesciences Corp..

Edwards Lifesciences Corp. has a beta of 0.955, which suggesting that the stock is 4.496% less volatile than S&P 500. In comparison Artivion, Inc. has a beta of 1.587, suggesting its more volatile than the S&P 500 by 58.733%.

Edwards Lifesciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Artivion, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences Corp. pays -- of its earnings as a dividend. Artivion, Inc. pays out -- of its earnings as a dividend.

Edwards Lifesciences Corp. quarterly revenues are $1.6B, which are larger than Artivion, Inc. quarterly revenues of $113.4M. Edwards Lifesciences Corp.'s net income of $292.3M is higher than Artivion, Inc.'s net income of $6.5M. Notably, Edwards Lifesciences Corp.'s price-to-earnings ratio is 36.24x while Artivion, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences Corp. is 8.51x versus 4.68x for Artivion, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of 18.82% compared to Edwards Lifesciences Corp.'s net margin of 14.91%. Edwards Lifesciences Corp.'s return on equity of 13.19% beat Boston Scientific Corp.'s return on equity of 12.46%.

Edwards Lifesciences Corp. has a consensus price target of $96.44, signalling upside risk potential of 13.29%. On the other hand Boston Scientific Corp. has an analysts' consensus of $125.45 which suggests that it could grow by 28.48%. Given that Boston Scientific Corp. has higher upside potential than Edwards Lifesciences Corp., analysts believe Boston Scientific Corp. is more attractive than Edwards Lifesciences Corp..

Edwards Lifesciences Corp. has a beta of 0.955, which suggesting that the stock is 4.496% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 33.029%.

Edwards Lifesciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences Corp. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Edwards Lifesciences Corp. quarterly revenues are $1.6B, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Edwards Lifesciences Corp.'s net income of $292.3M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Edwards Lifesciences Corp.'s price-to-earnings ratio is 36.24x while Boston Scientific Corp.'s PE ratio is 52.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences Corp. is 8.51x versus 7.53x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical, Inc. has a net margin of 18.82% compared to Edwards Lifesciences Corp.'s net margin of 15.47%. Edwards Lifesciences Corp.'s return on equity of 13.19% beat Globus Medical, Inc.'s return on equity of 10.08%.

Edwards Lifesciences Corp. has a consensus price target of $96.44, signalling upside risk potential of 13.29%. On the other hand Globus Medical, Inc. has an analysts' consensus of $106.40 which suggests that it could grow by 12.63%. Given that Edwards Lifesciences Corp. has higher upside potential than Globus Medical, Inc., analysts believe Edwards Lifesciences Corp. is more attractive than Globus Medical, Inc..

Edwards Lifesciences Corp. has a beta of 0.955, which suggesting that the stock is 4.496% less volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.064, suggesting its more volatile than the S&P 500 by 6.426%.

Edwards Lifesciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences Corp. pays -- of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend.

Edwards Lifesciences Corp. quarterly revenues are $1.6B, which are larger than Globus Medical, Inc. quarterly revenues of $769M. Edwards Lifesciences Corp.'s net income of $292.3M is higher than Globus Medical, Inc.'s net income of $119M. Notably, Edwards Lifesciences Corp.'s price-to-earnings ratio is 36.24x while Globus Medical, Inc.'s PE ratio is 30.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences Corp. is 8.51x versus 4.70x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pulse Biosciences, Inc. has a net margin of 18.82% compared to Edwards Lifesciences Corp.'s net margin of -22540.7%. Edwards Lifesciences Corp.'s return on equity of 13.19% beat Pulse Biosciences, Inc.'s return on equity of -73.32%.

Edwards Lifesciences Corp. has a consensus price target of $96.44, signalling upside risk potential of 13.29%. On the other hand Pulse Biosciences, Inc. has an analysts' consensus of $22.00 which suggests that it could grow by 51.83%. Given that Pulse Biosciences, Inc. has higher upside potential than Edwards Lifesciences Corp., analysts believe Pulse Biosciences, Inc. is more attractive than Edwards Lifesciences Corp..

Edwards Lifesciences Corp. has a beta of 0.955, which suggesting that the stock is 4.496% less volatile than S&P 500. In comparison Pulse Biosciences, Inc. has a beta of 1.687, suggesting its more volatile than the S&P 500 by 68.669%.

Edwards Lifesciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pulse Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences Corp. pays -- of its earnings as a dividend. Pulse Biosciences, Inc. pays out -- of its earnings as a dividend.

Edwards Lifesciences Corp. quarterly revenues are $1.6B, which are larger than Pulse Biosciences, Inc. quarterly revenues of $86K. Edwards Lifesciences Corp.'s net income of $292.3M is higher than Pulse Biosciences, Inc.'s net income of -$19.4M. Notably, Edwards Lifesciences Corp.'s price-to-earnings ratio is 36.24x while Pulse Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences Corp. is 8.51x versus 11,113.62x for Pulse Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.